View ValuationTitan Biotech 将来の成長Future 基準チェック /06現在、 Titan Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長19.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 20Titan Biotech Limited to Report Fiscal Year 2026 Results on May 30, 2026Titan Biotech Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Valuation Update With 7 Day Price Move • Apr 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹410, the stock trades at a trailing P/E ratio of 62.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 775% over the past three years.Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹458, the stock trades at a trailing P/E ratio of 69.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 1,008% over the past three years.Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹276, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 556% over the past three years.New Risk • Feb 19New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹2.15b market cap, or US$23.6m).New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹10.32 (vs ₹5.31 in 3Q 2025)Third quarter 2026 results: EPS: ₹10.32 (up from ₹5.31 in 3Q 2025). Revenue: ₹577.6m (up 51% from 3Q 2025). Net income: ₹85.3m (up 94% from 3Q 2025). Profit margin: 15% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 74% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹1,212, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 437% over the past three years.お知らせ • Feb 03Titan Biotech Limited to Report Q3, 2026 Results on Feb 12, 2026Titan Biotech Limited announced that they will report Q3, 2026 results on Feb 12, 2026Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,088, the stock trades at a trailing P/E ratio of 39x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 255% over the past three years.お知らせ • Nov 04Titan Biotech Limited to Report Q2, 2026 Results on Nov 11, 2025Titan Biotech Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 11, 2025Valuation Update With 7 Day Price Move • Oct 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹1,131, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 330% over the past three years.Valuation Update With 7 Day Price Move • Sep 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹781, the stock trades at a trailing P/E ratio of 29.3x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 183% over the past three years.Upcoming Dividend • Sep 12Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 19 September 2025. Payment date: 26 October 2025. Payout ratio is a comfortable 7.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (₹3.86b market cap, or US$44.0m).Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹547, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 123% over the past three years.Declared Dividend • Aug 15Dividend of ₹2.00 announcedDividend of ₹2.00 is the same as last year. Ex-date: 19th September 2025 Payment date: 26th October 2025 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (8% earnings payout ratio) and cash flows (15% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.3% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Aug 14Titan Biotech Limited, Annual General Meeting, Sep 26, 2025Titan Biotech Limited, Annual General Meeting, Sep 26, 2025, at 15:00 Indian Standard Time.Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹8.30 (vs ₹7.74 in 1Q 2025)First quarter 2026 results: EPS: ₹8.30 (up from ₹7.74 in 1Q 2025). Revenue: ₹472.2m (up 9.5% from 1Q 2025). Net income: ₹68.6m (up 7.2% from 1Q 2025). Profit margin: 14% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.お知らせ • Aug 02Titan Biotech Limited to Report Q1, 2026 Results on Aug 13, 2025Titan Biotech Limited announced that they will report Q1, 2026 results on Aug 13, 2025Reported Earnings • May 31Full year 2025 earnings released: EPS: ₹26.06 (vs ₹30.08 in FY 2024)Full year 2025 results: EPS: ₹26.06 (down from ₹30.08 in FY 2024). Revenue: ₹1.60b (down 2.3% from FY 2024). Net income: ₹215.3m (down 13% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.お知らせ • May 26Titan Biotech Limited to Report Q4, 2025 Results on May 30, 2025Titan Biotech Limited announced that they will report Q4, 2025 results on May 30, 2025Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹5.31 (vs ₹8.68 in 3Q 2024)Third quarter 2025 results: EPS: ₹5.31 (down from ₹8.68 in 3Q 2024). Revenue: ₹398.7m (down 13% from 3Q 2024). Net income: ₹43.9m (down 39% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₹543, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 105% over the past three years.お知らせ • Feb 03Titan Biotech Limited to Report Q3, 2025 Results on Feb 12, 2025Titan Biotech Limited announced that they will report Q3, 2025 results on Feb 12, 2025Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹8.10 (vs ₹7.89 in 2Q 2024)Second quarter 2025 results: EPS: ₹8.10 (up from ₹7.89 in 2Q 2024). Revenue: ₹402.1m (down 7.4% from 2Q 2024). Net income: ₹67.0m (up 2.7% from 2Q 2024). Profit margin: 17% (up from 15% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.お知らせ • Nov 06Titan Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024Titan Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹920, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 196% over the past three years.Upcoming Dividend • Sep 19Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 6.7% and the cash payout ratio is 92%. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%).Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹722, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years.Declared Dividend • Sep 05Dividend increased to ₹2.00Dividend of ₹2.00 is 11% higher than last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (14% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 41% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Sep 04Titan Biotech Limited, Annual General Meeting, Sep 30, 2024Titan Biotech Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2025 earnings released: EPS: ₹7.74 (vs ₹7.47 in 1Q 2024)First quarter 2025 results: EPS: ₹7.74 (up from ₹7.47 in 1Q 2024). Revenue: ₹431.1m (up 24% from 1Q 2024). Net income: ₹64.0m (up 3.9% from 1Q 2024). Profit margin: 15% (down from 18% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.お知らせ • Aug 04Titan Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024Titan Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹30.07 (vs ₹30.06 in FY 2023)Full year 2024 results: EPS: ₹30.07 (up from ₹30.06 in FY 2023). Revenue: ₹1.64b (up 14% from FY 2023). Net income: ₹248.5m (flat on FY 2023). Profit margin: 15% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.お知らせ • May 30Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2024Titan Biotech Limited have recommended a dividend of INR 2.00/- per equity share for the Financial Year ended on 31st March, 2024. The said dividend, if declared at the upcoming Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.Valuation Update With 7 Day Price Move • May 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹597, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 100% over the past three years.お知らせ • May 20Titan Biotech Limited to Report Q4, 2024 Results on May 29, 2024Titan Biotech Limited announced that they will report Q4, 2024 results on May 29, 2024Valuation Update With 7 Day Price Move • Feb 19Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹594, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 249% over the past three years.Reported Earnings • Feb 13Third quarter 2024 earnings released: EPS: ₹8.68 (vs ₹3.95 in 3Q 2023)Third quarter 2024 results: EPS: ₹8.68 (up from ₹3.95 in 3Q 2023). Revenue: ₹464.2m (up 53% from 3Q 2023). Net income: ₹71.7m (up 120% from 3Q 2023). Profit margin: 16% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings.New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹3.83b market cap, or US$46.2m).お知らせ • Feb 01Titan Biotech Limited to Report Q3, 2024 Results on Feb 12, 2024Titan Biotech Limited announced that they will report Q3, 2024 results on Feb 12, 2024Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹502, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 200% over the past three years.Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹7.89 (vs ₹11.04 in 2Q 2023)Second quarter 2024 results: EPS: ₹7.89 (down from ₹11.04 in 2Q 2023). Revenue: ₹439.8m (up 5.1% from 2Q 2023). Net income: ₹65.2m (down 28% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings.Upcoming Dividend • Sep 15Upcoming dividend of ₹1.80 per share at 0.5% yieldEligible shareholders must have bought the stock before 22 September 2023. Payment date: 29 October 2023. Payout ratio is a comfortable 6.0% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).Reported Earnings • Sep 06Full year 2023 earnings released: EPS: ₹25.44 (vs ₹30.66 in FY 2022)Full year 2023 results: EPS: ₹25.44 (down from ₹30.66 in FY 2022). Revenue: ₹1.46b (down 4.6% from FY 2022). Net income: ₹248.4m (down 1.9% from FY 2022). Profit margin: 17% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 02Titan Biotech Limited, Annual General Meeting, Sep 29, 2023Titan Biotech Limited, Annual General Meeting, Sep 29, 2023, at 15:00 Indian Standard Time.New Risk • Aug 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹2.76b market cap, or US$33.3m).Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹334, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 228% over the past three years.お知らせ • Aug 01Titan Biotech Limited to Report Q1, 2024 Results on Aug 10, 2023Titan Biotech Limited announced that they will report Q1, 2024 results on Aug 10, 2023お知らせ • Jul 27Titan Biotech Limited Announces Resignation of Rekha Dalmia as Non-Executive Independent DirectorTitan Biotech Limited announced that Mrs. Rekha Dalmia has resigned from directorship (In capacity of non-executive independent director) of the company with effect from 25 July 2023, due to pre-occupation and other personal commitments. Consequently, she shall also cease to be Chairman/Member of Nomination and remuneration committee, Corporate Social Responsibility Committee and Audit Committee of the Company.お知らせ • May 31Titan Biotech Limited Recommends Dividend for the Financial Year Ended on March 31, 2023Titan Biotech Limited announced that at the board meeting held on May 29, 2023, the company recommended of a dividend of INR 1.80/- (One Rupees Eighty Paisa Only) per equity share for the Financial Year ended on March 31, 2023.お知らせ • May 17Titan Biotech Limited to Report Q4, 2023 Results on May 29, 2023Titan Biotech Limited announced that they will report Q4, 2023 results on May 29, 2023Reported Earnings • Feb 05Third quarter 2023 earnings released: EPS: ₹3.95 (vs ₹6.33 in 3Q 2022)Third quarter 2023 results: EPS: ₹3.95 (down from ₹6.33 in 3Q 2022). Revenue: ₹306.1m (down 15% from 3Q 2022). Net income: ₹32.6m (down 38% from 3Q 2022). Profit margin: 11% (down from 14% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 27Titan Biotech Limited to Report Q3, 2023 Results on Feb 04, 2023Titan Biotech Limited announced that they will report Q3, 2023 results on Feb 04, 2023Reported Earnings • Nov 19Second quarter 2023 earnings released: EPS: ₹11.04 (vs ₹7.74 in 2Q 2022)Second quarter 2023 results: EPS: ₹11.04 (up from ₹7.74 in 2Q 2022). Revenue: ₹426.9m (up 4.5% from 2Q 2022). Net income: ₹91.3m (up 43% from 2Q 2022). Profit margin: 21% (up from 16% in 2Q 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Non-Executive Independent Director Rohit Jain was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buying Opportunity • Nov 11Now 21% undervaluedOver the last 90 days, the stock is up 22%. The fair value is estimated to be ₹360, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 54%.お知らせ • Nov 05Titan Biotech Limited to Report Q2, 2023 Results on Nov 14, 2022Titan Biotech Limited announced that they will report Q2, 2023 results on Nov 14, 2022お知らせ • Oct 02Titan Biotech Limited Appoints Raja Singla as Executive Director, with Effect from October 1, 2022Titan Biotech Limited approved the appointment of Mr. Raja Singla (DIN: 03523719) in the category of Executive Director of the Company for a term of 5 (five) years with effect from October 1, 2022. Currently, Mr. Raja Singla is associated with Company as a Senior Vice President- Production of the Company from 01 October, 2019. Experience in Production of over 8 years in Phoenix Bio Sciences Private Limited and over 2.5 years in Titan Biotech Limited.Mr. Naresh Kumar Singla, Managing Director is Father of appointee Director.Upcoming Dividend • Sep 15Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 30 October 2022. Payout ratio is a comfortable 4.9% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).Reported Earnings • Sep 02Full year 2022 earnings released: EPS: ₹30.66 (vs ₹36.71 in FY 2021)Full year 2022 results: EPS: ₹30.66 (down from ₹36.71 in FY 2021). Revenue: ₹1.54b (up 8.1% from FY 2021). Net income: ₹253.3m (down 17% from FY 2021). Profit margin: 17% (down from 21% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 103% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 27Titan Biotech Limited, Annual General Meeting, Sep 30, 2022Titan Biotech Limited, Annual General Meeting, Sep 30, 2022, at 15:00 Indian Standard Time.お知らせ • May 31Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2022The Board of Directors of Titan Biotech Limited have recommended a dividend of INR 1.50/- (Rupees One Fifty Paisa Only) per equity share for the Financial Year ended on 31 March, 2022. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Rohit Jain was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹226, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 387% over the past three years.Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹6.33 (down from ₹8.02 in 3Q 2021). Revenue: ₹359.7m (up 4.0% from 3Q 2021). Net income: ₹52.3m (down 21% from 3Q 2021). Profit margin: 14% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 78% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 18Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹260, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 405% over the past three years.Upcoming Dividend • Sep 09Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 24 October 2021. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).Executive Departure • Aug 18Independent Non Executive Chairman Jai Bansal has left the companyOn the 10th of August, Jai Bansal's tenure as Independent Non Executive Chairman ended after 2.4 years in the role. We don't have any record of a personal shareholding under Jai's name. Jai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years.Reported Earnings • Aug 12First quarter 2022 earnings released: EPS ₹10.56 (vs ₹15.42 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: ₹415.8m (up 5.5% from 1Q 2021). Net income: ₹87.2m (down 32% from 1Q 2021). Profit margin: 21% (down from 32% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹396, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 635% over the past three years.Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹36.71 (vs ₹8.55 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹1.42b (up 79% from FY 2020). Net income: ₹303.4m (up 329% from FY 2020). Profit margin: 21% (up from 8.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year whereas the company’s share price has increased by 83% per year.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹349, the stock trades at a trailing P/E ratio of 10.1x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 551% over the past three years.Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improved over the past weekAfter last week's 34% share price gain to ₹284, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 364% over the past three years.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹202, the stock is trading at a trailing P/E ratio of 5.9x, up from the previous P/E ratio of 5x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 221%.Is New 90 Day High Low • Mar 08New 90-day high: ₹202The company is up 43% from its price of ₹142 on 08 December 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹201, the stock is trading at a trailing P/E ratio of 5.8x, up from the previous P/E ratio of 4.9x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 191%.Is New 90 Day High Low • Feb 11New 90-day high: ₹192The company is up 44% from its price of ₹133 on 13 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.Reported Earnings • Jan 30Third quarter 2021 earnings released: EPS ₹8.02 (vs ₹2.13 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹346.0m (up 84% from 3Q 2020). Net income: ₹66.2m (up 276% from 3Q 2020). Profit margin: 19% (up from 9.4% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 19Titan Biotech Limited to Report Q3, 2021 Results on Jan 27, 2021Titan Biotech Limited announced that they will report Q3, 2021 results on Jan 27, 2021Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹180, the stock is trading at a trailing P/E ratio of 6.3x, up from the previous P/E ratio of 5.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 170%.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹152, the stock is trading at a trailing P/E ratio of 5.3x, up from the previous P/E ratio of 4.5x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 158%.Is New 90 Day High Low • Nov 10New 90-day low: ₹126The company is down 4.0% from its price of ₹131 on 12 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 22% share price decline to ₹147, the stock is trading at a trailing P/E ratio of 5.1x, down from the previous P/E ratio of 6.5x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 141%.Reported Earnings • Oct 21First half earnings releasedOver the last 12 months the company has reported total profits of ₹236.3m, up 377% from the prior year. Total revenue was ₹1.11b over the last 12 months, up 52% from the prior year.Is New 90 Day High Low • Oct 16New 90-day high: ₹185The company is up 130% from its price of ₹80.50 on 17 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.Valuation Update With 7 Day Price Move • Oct 13Market bids up stock over the past weekAfter last week's 16% share price gain to ₹171, the stock is trading at a trailing P/E ratio of 7.9x, up from the previous P/E ratio of 6.9x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 179%.お知らせ • Oct 10Titan Biotech Limited to Report Q2, 2020 Results on Oct 19, 2020Titan Biotech Limited announced that they will report Q2, 2020 results on Oct 19, 2020お知らせ • Jun 20Titan Biotech Limited to Report Fiscal Year 2020 Results on Jun 30, 2020Titan Biotech Limited announced that they will report fiscal year 2020 results on Jun 30, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Titan Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:524717 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251,925272N/AN/AN/A9/30/20251,743231143208N/A6/30/20251,598220N/AN/AN/A3/31/20251,565215107201N/A12/31/20241,612225N/AN/AN/A9/30/20241,68925372233N/A6/30/20241,724251N/AN/AN/A3/31/20241,64124916211N/A12/31/20231,610248N/AN/AN/A9/30/20231,45320982224N/A6/30/20231,403227N/AN/AN/A3/31/20231,44024884212N/A12/31/20221,403249N/AN/AN/A9/30/20221,46426840168N/A6/30/20221,50024966186N/A3/31/20221,235217157220N/A12/31/20211,5382413136N/A9/30/20211,525255145186N/A6/30/20211,443263170205N/A3/31/20211,422303161191N/A12/31/20201,268285209231N/A9/30/20201,109236N/AN/AN/A6/30/2020968178N/AN/AN/A3/31/2020794716161N/A12/31/201976658N/AN/AN/A9/30/201972849N/AN/AN/A6/30/201971346N/AN/AN/A3/31/201964935N/A55N/A12/31/201865946N/AN/AN/A9/30/201866241N/AN/AN/A6/30/201862734N/AN/AN/A3/31/201857425N/A19N/A12/31/201758727N/AN/AN/A9/30/201755722N/AN/AN/A6/30/201753523N/AN/AN/A3/31/201752722N/A1N/A12/31/201650318N/AN/AN/A9/30/201649420N/AN/AN/A6/30/201648418N/AN/AN/A3/31/201645818N/A48N/A12/31/201545116N/AN/AN/A9/30/201541916N/AN/AN/A6/30/201540816N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 524717の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 524717の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 524717の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 524717の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 524717の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 524717の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:03終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Titan Biotech Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 20Titan Biotech Limited to Report Fiscal Year 2026 Results on May 30, 2026Titan Biotech Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹410, the stock trades at a trailing P/E ratio of 62.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 775% over the past three years.
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹458, the stock trades at a trailing P/E ratio of 69.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 1,008% over the past three years.
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹276, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 556% over the past three years.
New Risk • Feb 19New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹2.15b market cap, or US$23.6m).
New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹10.32 (vs ₹5.31 in 3Q 2025)Third quarter 2026 results: EPS: ₹10.32 (up from ₹5.31 in 3Q 2025). Revenue: ₹577.6m (up 51% from 3Q 2025). Net income: ₹85.3m (up 94% from 3Q 2025). Profit margin: 15% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 74% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹1,212, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 437% over the past three years.
お知らせ • Feb 03Titan Biotech Limited to Report Q3, 2026 Results on Feb 12, 2026Titan Biotech Limited announced that they will report Q3, 2026 results on Feb 12, 2026
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,088, the stock trades at a trailing P/E ratio of 39x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 255% over the past three years.
お知らせ • Nov 04Titan Biotech Limited to Report Q2, 2026 Results on Nov 11, 2025Titan Biotech Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 11, 2025
Valuation Update With 7 Day Price Move • Oct 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹1,131, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 330% over the past three years.
Valuation Update With 7 Day Price Move • Sep 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹781, the stock trades at a trailing P/E ratio of 29.3x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 183% over the past three years.
Upcoming Dividend • Sep 12Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 19 September 2025. Payment date: 26 October 2025. Payout ratio is a comfortable 7.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (₹3.86b market cap, or US$44.0m).
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹547, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 123% over the past three years.
Declared Dividend • Aug 15Dividend of ₹2.00 announcedDividend of ₹2.00 is the same as last year. Ex-date: 19th September 2025 Payment date: 26th October 2025 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (8% earnings payout ratio) and cash flows (15% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.3% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 14Titan Biotech Limited, Annual General Meeting, Sep 26, 2025Titan Biotech Limited, Annual General Meeting, Sep 26, 2025, at 15:00 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹8.30 (vs ₹7.74 in 1Q 2025)First quarter 2026 results: EPS: ₹8.30 (up from ₹7.74 in 1Q 2025). Revenue: ₹472.2m (up 9.5% from 1Q 2025). Net income: ₹68.6m (up 7.2% from 1Q 2025). Profit margin: 14% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
お知らせ • Aug 02Titan Biotech Limited to Report Q1, 2026 Results on Aug 13, 2025Titan Biotech Limited announced that they will report Q1, 2026 results on Aug 13, 2025
Reported Earnings • May 31Full year 2025 earnings released: EPS: ₹26.06 (vs ₹30.08 in FY 2024)Full year 2025 results: EPS: ₹26.06 (down from ₹30.08 in FY 2024). Revenue: ₹1.60b (down 2.3% from FY 2024). Net income: ₹215.3m (down 13% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
お知らせ • May 26Titan Biotech Limited to Report Q4, 2025 Results on May 30, 2025Titan Biotech Limited announced that they will report Q4, 2025 results on May 30, 2025
Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹5.31 (vs ₹8.68 in 3Q 2024)Third quarter 2025 results: EPS: ₹5.31 (down from ₹8.68 in 3Q 2024). Revenue: ₹398.7m (down 13% from 3Q 2024). Net income: ₹43.9m (down 39% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₹543, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 105% over the past three years.
お知らせ • Feb 03Titan Biotech Limited to Report Q3, 2025 Results on Feb 12, 2025Titan Biotech Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹8.10 (vs ₹7.89 in 2Q 2024)Second quarter 2025 results: EPS: ₹8.10 (up from ₹7.89 in 2Q 2024). Revenue: ₹402.1m (down 7.4% from 2Q 2024). Net income: ₹67.0m (up 2.7% from 2Q 2024). Profit margin: 17% (up from 15% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
お知らせ • Nov 06Titan Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024Titan Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹920, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 196% over the past three years.
Upcoming Dividend • Sep 19Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 6.7% and the cash payout ratio is 92%. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%).
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹722, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years.
Declared Dividend • Sep 05Dividend increased to ₹2.00Dividend of ₹2.00 is 11% higher than last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (14% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 41% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Sep 04Titan Biotech Limited, Annual General Meeting, Sep 30, 2024Titan Biotech Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2025 earnings released: EPS: ₹7.74 (vs ₹7.47 in 1Q 2024)First quarter 2025 results: EPS: ₹7.74 (up from ₹7.47 in 1Q 2024). Revenue: ₹431.1m (up 24% from 1Q 2024). Net income: ₹64.0m (up 3.9% from 1Q 2024). Profit margin: 15% (down from 18% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
お知らせ • Aug 04Titan Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024Titan Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹30.07 (vs ₹30.06 in FY 2023)Full year 2024 results: EPS: ₹30.07 (up from ₹30.06 in FY 2023). Revenue: ₹1.64b (up 14% from FY 2023). Net income: ₹248.5m (flat on FY 2023). Profit margin: 15% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
お知らせ • May 30Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2024Titan Biotech Limited have recommended a dividend of INR 2.00/- per equity share for the Financial Year ended on 31st March, 2024. The said dividend, if declared at the upcoming Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.
Valuation Update With 7 Day Price Move • May 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹597, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 100% over the past three years.
お知らせ • May 20Titan Biotech Limited to Report Q4, 2024 Results on May 29, 2024Titan Biotech Limited announced that they will report Q4, 2024 results on May 29, 2024
Valuation Update With 7 Day Price Move • Feb 19Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹594, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 249% over the past three years.
Reported Earnings • Feb 13Third quarter 2024 earnings released: EPS: ₹8.68 (vs ₹3.95 in 3Q 2023)Third quarter 2024 results: EPS: ₹8.68 (up from ₹3.95 in 3Q 2023). Revenue: ₹464.2m (up 53% from 3Q 2023). Net income: ₹71.7m (up 120% from 3Q 2023). Profit margin: 16% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings.
New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹3.83b market cap, or US$46.2m).
お知らせ • Feb 01Titan Biotech Limited to Report Q3, 2024 Results on Feb 12, 2024Titan Biotech Limited announced that they will report Q3, 2024 results on Feb 12, 2024
Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹502, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 200% over the past three years.
Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹7.89 (vs ₹11.04 in 2Q 2023)Second quarter 2024 results: EPS: ₹7.89 (down from ₹11.04 in 2Q 2023). Revenue: ₹439.8m (up 5.1% from 2Q 2023). Net income: ₹65.2m (down 28% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings.
Upcoming Dividend • Sep 15Upcoming dividend of ₹1.80 per share at 0.5% yieldEligible shareholders must have bought the stock before 22 September 2023. Payment date: 29 October 2023. Payout ratio is a comfortable 6.0% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).
Reported Earnings • Sep 06Full year 2023 earnings released: EPS: ₹25.44 (vs ₹30.66 in FY 2022)Full year 2023 results: EPS: ₹25.44 (down from ₹30.66 in FY 2022). Revenue: ₹1.46b (down 4.6% from FY 2022). Net income: ₹248.4m (down 1.9% from FY 2022). Profit margin: 17% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 02Titan Biotech Limited, Annual General Meeting, Sep 29, 2023Titan Biotech Limited, Annual General Meeting, Sep 29, 2023, at 15:00 Indian Standard Time.
New Risk • Aug 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹2.76b market cap, or US$33.3m).
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹334, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 228% over the past three years.
お知らせ • Aug 01Titan Biotech Limited to Report Q1, 2024 Results on Aug 10, 2023Titan Biotech Limited announced that they will report Q1, 2024 results on Aug 10, 2023
お知らせ • Jul 27Titan Biotech Limited Announces Resignation of Rekha Dalmia as Non-Executive Independent DirectorTitan Biotech Limited announced that Mrs. Rekha Dalmia has resigned from directorship (In capacity of non-executive independent director) of the company with effect from 25 July 2023, due to pre-occupation and other personal commitments. Consequently, she shall also cease to be Chairman/Member of Nomination and remuneration committee, Corporate Social Responsibility Committee and Audit Committee of the Company.
お知らせ • May 31Titan Biotech Limited Recommends Dividend for the Financial Year Ended on March 31, 2023Titan Biotech Limited announced that at the board meeting held on May 29, 2023, the company recommended of a dividend of INR 1.80/- (One Rupees Eighty Paisa Only) per equity share for the Financial Year ended on March 31, 2023.
お知らせ • May 17Titan Biotech Limited to Report Q4, 2023 Results on May 29, 2023Titan Biotech Limited announced that they will report Q4, 2023 results on May 29, 2023
Reported Earnings • Feb 05Third quarter 2023 earnings released: EPS: ₹3.95 (vs ₹6.33 in 3Q 2022)Third quarter 2023 results: EPS: ₹3.95 (down from ₹6.33 in 3Q 2022). Revenue: ₹306.1m (down 15% from 3Q 2022). Net income: ₹32.6m (down 38% from 3Q 2022). Profit margin: 11% (down from 14% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 27Titan Biotech Limited to Report Q3, 2023 Results on Feb 04, 2023Titan Biotech Limited announced that they will report Q3, 2023 results on Feb 04, 2023
Reported Earnings • Nov 19Second quarter 2023 earnings released: EPS: ₹11.04 (vs ₹7.74 in 2Q 2022)Second quarter 2023 results: EPS: ₹11.04 (up from ₹7.74 in 2Q 2022). Revenue: ₹426.9m (up 4.5% from 2Q 2022). Net income: ₹91.3m (up 43% from 2Q 2022). Profit margin: 21% (up from 16% in 2Q 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Non-Executive Independent Director Rohit Jain was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Nov 11Now 21% undervaluedOver the last 90 days, the stock is up 22%. The fair value is estimated to be ₹360, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 54%.
お知らせ • Nov 05Titan Biotech Limited to Report Q2, 2023 Results on Nov 14, 2022Titan Biotech Limited announced that they will report Q2, 2023 results on Nov 14, 2022
お知らせ • Oct 02Titan Biotech Limited Appoints Raja Singla as Executive Director, with Effect from October 1, 2022Titan Biotech Limited approved the appointment of Mr. Raja Singla (DIN: 03523719) in the category of Executive Director of the Company for a term of 5 (five) years with effect from October 1, 2022. Currently, Mr. Raja Singla is associated with Company as a Senior Vice President- Production of the Company from 01 October, 2019. Experience in Production of over 8 years in Phoenix Bio Sciences Private Limited and over 2.5 years in Titan Biotech Limited.Mr. Naresh Kumar Singla, Managing Director is Father of appointee Director.
Upcoming Dividend • Sep 15Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 30 October 2022. Payout ratio is a comfortable 4.9% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).
Reported Earnings • Sep 02Full year 2022 earnings released: EPS: ₹30.66 (vs ₹36.71 in FY 2021)Full year 2022 results: EPS: ₹30.66 (down from ₹36.71 in FY 2021). Revenue: ₹1.54b (up 8.1% from FY 2021). Net income: ₹253.3m (down 17% from FY 2021). Profit margin: 17% (down from 21% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 103% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 27Titan Biotech Limited, Annual General Meeting, Sep 30, 2022Titan Biotech Limited, Annual General Meeting, Sep 30, 2022, at 15:00 Indian Standard Time.
お知らせ • May 31Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2022The Board of Directors of Titan Biotech Limited have recommended a dividend of INR 1.50/- (Rupees One Fifty Paisa Only) per equity share for the Financial Year ended on 31 March, 2022. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Rohit Jain was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹226, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 387% over the past three years.
Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹6.33 (down from ₹8.02 in 3Q 2021). Revenue: ₹359.7m (up 4.0% from 3Q 2021). Net income: ₹52.3m (down 21% from 3Q 2021). Profit margin: 14% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 78% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 18Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹260, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 405% over the past three years.
Upcoming Dividend • Sep 09Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 24 October 2021. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).
Executive Departure • Aug 18Independent Non Executive Chairman Jai Bansal has left the companyOn the 10th of August, Jai Bansal's tenure as Independent Non Executive Chairman ended after 2.4 years in the role. We don't have any record of a personal shareholding under Jai's name. Jai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years.
Reported Earnings • Aug 12First quarter 2022 earnings released: EPS ₹10.56 (vs ₹15.42 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: ₹415.8m (up 5.5% from 1Q 2021). Net income: ₹87.2m (down 32% from 1Q 2021). Profit margin: 21% (down from 32% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹396, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 635% over the past three years.
Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹36.71 (vs ₹8.55 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹1.42b (up 79% from FY 2020). Net income: ₹303.4m (up 329% from FY 2020). Profit margin: 21% (up from 8.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year whereas the company’s share price has increased by 83% per year.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹349, the stock trades at a trailing P/E ratio of 10.1x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 551% over the past three years.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improved over the past weekAfter last week's 34% share price gain to ₹284, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 364% over the past three years.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹202, the stock is trading at a trailing P/E ratio of 5.9x, up from the previous P/E ratio of 5x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 221%.
Is New 90 Day High Low • Mar 08New 90-day high: ₹202The company is up 43% from its price of ₹142 on 08 December 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹201, the stock is trading at a trailing P/E ratio of 5.8x, up from the previous P/E ratio of 4.9x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 191%.
Is New 90 Day High Low • Feb 11New 90-day high: ₹192The company is up 44% from its price of ₹133 on 13 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.
Reported Earnings • Jan 30Third quarter 2021 earnings released: EPS ₹8.02 (vs ₹2.13 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹346.0m (up 84% from 3Q 2020). Net income: ₹66.2m (up 276% from 3Q 2020). Profit margin: 19% (up from 9.4% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 19Titan Biotech Limited to Report Q3, 2021 Results on Jan 27, 2021Titan Biotech Limited announced that they will report Q3, 2021 results on Jan 27, 2021
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹180, the stock is trading at a trailing P/E ratio of 6.3x, up from the previous P/E ratio of 5.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 170%.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹152, the stock is trading at a trailing P/E ratio of 5.3x, up from the previous P/E ratio of 4.5x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 158%.
Is New 90 Day High Low • Nov 10New 90-day low: ₹126The company is down 4.0% from its price of ₹131 on 12 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 22% share price decline to ₹147, the stock is trading at a trailing P/E ratio of 5.1x, down from the previous P/E ratio of 6.5x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 141%.
Reported Earnings • Oct 21First half earnings releasedOver the last 12 months the company has reported total profits of ₹236.3m, up 377% from the prior year. Total revenue was ₹1.11b over the last 12 months, up 52% from the prior year.
Is New 90 Day High Low • Oct 16New 90-day high: ₹185The company is up 130% from its price of ₹80.50 on 17 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.
Valuation Update With 7 Day Price Move • Oct 13Market bids up stock over the past weekAfter last week's 16% share price gain to ₹171, the stock is trading at a trailing P/E ratio of 7.9x, up from the previous P/E ratio of 6.9x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 179%.
お知らせ • Oct 10Titan Biotech Limited to Report Q2, 2020 Results on Oct 19, 2020Titan Biotech Limited announced that they will report Q2, 2020 results on Oct 19, 2020
お知らせ • Jun 20Titan Biotech Limited to Report Fiscal Year 2020 Results on Jun 30, 2020Titan Biotech Limited announced that they will report fiscal year 2020 results on Jun 30, 2020